Literature DB >> 8426740

Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

M Fritsche1, C Haessler, G Brandner.   

Abstract

Cancer therapy drugs, such as diamminedichloroplatinum (cisplatin), mitomycin C, etoposide and a number of other compounds, as well as energy-rich radiation, are known to act on cellular DNA. These agents are shown to induce nuclear accumulation of the so-called tumor-suppressor protein p53 in fibroblastoid cells, as well as in epithelioid normal and immortalized cells of murine, simian, and human origin. p53 accumulation starts a few hours after treatment and can remain detectable in surviving cells for at least 20 days. Accumulation occurs because of increased p53 protein stability and depends on ongoing translation. It is not the result of enhanced gene expression. A number of cell cycle inhibitors do not affect p53 protein accumulation, suggesting that the process may start from several points in the cell cycle. Since the increase in the nuclear p53 protein levels occurs within a few hours in most of the treated normal diploid cells, it is unlikely that the accumulated p53 protein is derived from a mutated p53 gene. The results obtained are in accordance with the view that the DNA damage-induced p53 accumulation may either inhibit cell growth, allowing DNA repair processes, or, in the case of severe damage, initiate apoptosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426740

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  160 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

3.  Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks.

Authors:  K Nakagawa; Y Taya; K Tamai; M Yamaizumi
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

4.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

5.  The tumour suppressor protein p53 can repress transcription of cyclin B.

Authors:  K Krause; M Wasner; W Reinhard; U Haugwitz; C L Dohna; J Mössner; K Engeland
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

Review 6.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

7.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

8.  The hepatitis B virus X gene induces p53-mediated programmed cell death.

Authors:  P Chirillo; S Pagano; G Natoli; P L Puri; V L Burgio; C Balsano; M Levrero
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

9.  Higher Level of P-glycoprotein Expression in Human Breast Cancer Cells after Radiation Therapy.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

10.  Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Authors:  Kalpana Mujoo; Masayuki Watanabe; Junichi Nakamura; Abdul R Khokhar; Zahid H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.